A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal

被引:42
作者
Rothwell, Joanne C. [1 ,3 ]
Julious, Steven A. [1 ]
Cooper, Cindy L. [2 ]
机构
[1] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England
[2] Univ Sheffield, Sheffield Clin Trials Unit, Sheffield, S Yorkshire, England
[3] Univ Sheffield, Sch Hlth & Related Res ScHARR, Med Stat Grp, Regent Court, 30 Regent St, Sheffield S1 4DA, S Yorkshire, England
关键词
Randomised controlled trial; Target difference; Effect size; HTA; Health technology assessment; SAMPLE-SIZE; DIFFERENCE;
D O I
10.1186/s13063-018-2886-y
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BackgroundWhen designing a randomised controlled trial (RCT), an important consideration is the sample size required. This is calculated from several components; one of which is the target difference. This study aims to review the currently reported methods of elicitation of the target difference as well as to quantify the target differences used in Health Technology Assessment (HTA)-funded trials.MethodsTrials were identified from the National Institute of Health Research Health Technology Assessment journal. A total of 177 RCTs published between 2006 and 2016 were assessed for eligibility. Eligibility was established by the design of the trial and the quality of data available. The trial designs were parallel-group, superiority RCTs with a continuous primary endpoint. Data were extracted and the standardised anticipated and observed effect size estimates were calculated. Exclusion criteria was based on trials not providing enough detail in the sample size calculation and results, and trials not being of parallel-group, superiority design.ResultsA total of 107 RCTs were included in the study from 102 reports. The most commonly reported method for effect size derivation was a review of evidence and use of previous research (52.3%). This was common across all clinical areas. The median standardised target effect size was 0.30 (interquartile range: 0.20-0.38), with the median standardised observed effect size 0.11 (IQR 0.05-0.29). The maximum anticipated and observed effect sizes were 0.76 and 1.18, respectively. Only two trials had anticipated target values above 0.60.ConclusionThe most commonly reported method of elicitation of the target effect size is previous published research. The average target effect size was 0.3.A clear distinction between the target difference and the minimum clinically important difference is recommended when designing a trial. Transparent explanation of target difference elicitation is advised, with multiple methods including a review of evidence and opinion-seeking advised as the more optimal methods for effect size quantification.
引用
收藏
页数:13
相关论文
共 26 条
[1]   Patients' acceptance of anti hypertensive therapy to prevent cardiovascular disease: a comparison between South Asians and Caucasians in the United Kingdom [J].
Aarabi, Mohsen ;
Skinner, John ;
Price, Charles E. ;
Jackson, Peter R. .
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2008, 15 (01) :59-66
[2]   Sample Size in Obesity Trials: Patient Perspective Versus Current Practice [J].
Allison, David B. ;
Elobeid, Mai A. ;
Cope, Mark B. ;
Brock, David W. ;
Faith, Myles S. ;
Veur, Stephanie Vander ;
Berkowitz, Robert ;
Cutter, Gary ;
McVie, Theresa ;
Gadde, Kishore M. ;
Foster, Gary D. .
MEDICAL DECISION MAKING, 2010, 30 (01) :68-75
[4]  
[Anonymous], 2013, DESIGNING CLIN RES
[5]  
Cohen J., 1988, STAT POWER ANAL BEHA, DOI [10.4324/9780203771587, DOI 10.4324/9780203771587]
[6]  
Cook JA, 2018, BMJ
[7]   Choosing the target difference ('effect size') for a randomised controlled trial - DELTA2 guidance protocol [J].
Cook, Jonathan A. ;
Julious, Steven A. ;
Sones, William ;
Rothwell, Joanne C. ;
Ramsay, Craig R. ;
Hampson, Lisa V. ;
Emsley, Richard ;
Walters, Stephen J. ;
Hewitt, Catherine ;
Bland, Martin ;
Fergusson, Dean A. ;
Berlin, Jesse A. ;
Altman, Doug ;
Vale, Luke D. .
TRIALS, 2017, 18
[8]   Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers [J].
Cook, Jonathan A. ;
Hislop, Jenni ;
Altman, Douglas G. ;
Fayers, Peter ;
Briggs, Andrew H. ;
Ramsay, Craig R. ;
Norrie, John D. ;
Harvey, Ian M. ;
Buckley, Brian ;
Fergusson, Dean ;
Ford, Ian ;
Vale, Luke D. .
TRIALS, 2015, 16
[9]   Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review [J].
Cook, Jonathan A. ;
Hislop, Jennifer ;
Adewuyi, Temitope E. ;
Harrild, Kirsten ;
Altman, Douglas G. ;
Ramsay, Craig R. ;
Fraser, Cynthia ;
Buckley, Brian ;
Fayers, Peter ;
Harvey, Ian ;
Briggs, Andrew H. ;
Norrie, John D. ;
Fergusson, Dean ;
Ford, Ian ;
Vale, Luke D. .
HEALTH TECHNOLOGY ASSESSMENT, 2014, 18 (28) :1-+
[10]   Clinically Relevant Changes in Sexual Desire, Satisfying Sexual Activity and Personal Distress as Measured by the Profile of Female Sexual Function, Sexual Activity Log, and Personal Distress Scale in Postmenopausal Women with Hypoactive Sexual Desire Disorder [J].
DeRogatis, Leonard R. ;
Graziottin, Alessandra ;
Bitzer, Johannes ;
Schmitt, Sonja ;
Koochaki, Patricia E. ;
Rodenberg, Cynthia .
JOURNAL OF SEXUAL MEDICINE, 2009, 6 (01) :175-183